ACT granted CHA Biotech an Exclusive License to use and commercialize the Single Blastomere Technology in South Korea. Total payment to ACT for Exclusive License was $300,000.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.